Study to Develop a Prediction Model to Understand the Effect of Low-dose Aspirin on Cancer That Develops in the Colon and/or the Rectum, Diseases That Affects the Heart or Blood Vessels and Safety Outcomes in European Countries. The Study is Also Called PEACOS Model EU

Completed

Brief Summary: In this study researchers want to learn more about the effect of low-dose Aspirin on cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine before the anus), diseases that affects the heart or blood vessels and safety outcomes. Study will focus on two groups of adults aged 50-59 and 60-69 years having an increased risk of heart and/or blood vessel disease who are taking either low-dose aspirin or no low-dose aspirin for heart and/or blood vessel disease prevention. The model will be based on information publicly available either on government organization websites or in scientific journals. Based on these data researchers will focus in a first step to build a model of 2 million adults (1 million for each age group) for the UK population and in a second step, the model will be modified for use with other European countries, to reflect the epidemiology and guidelines for aspirin use in these countries.

Detailed Description: Observational Study Model is selected as "Other" - Reason: Individual-level state transition model simulating the number of events of CRC, CVD, safety events and deaths in hypothetical cohorts of 1 million adults aged 50-59 years and 1 million adults aged 60-69 years followed for 20 years or till death, whichever comes first. The hypothetical cohorts are reflective of a population eligible for taking aspirin for primary or secondary CVD prevention.

Time Perspective is also selected as "Other"

- Reason: Individual-level state transition model built mimicking the UK population using data published in scientific international peer-reviewed journals or published data from government agencies. In a second phase, the model results will be extrapolated to other EU countries, modifying the model parameters to reflect the other EU countries epidemiology.

Recruitment & Eligibility

Inclusion Criteria

European populations (UK and other European countries) of adults aged 50-59 and 60-69 years eligible for using aspirin for primary or secondary CVD prevention. Subjects are eligible when they have no contra-indications, and are at increased risk of CVD (primary prevention) or have suffered from a previous CVD event

Exclusion Criteria

Arm && Interventions

Group	Intervention	Description
Cohort 5	Acetylsalicylic Acid (Aspirin, BAYE4465)	hypothetical UK populations of adults aged 60-69 take low-dose aspirin for primary prevention
Cohort 6	Acetylsalicylic Acid (Aspirin, BAYE4465)	hypothetical UK populations of adults aged 60-69 take low-dose aspirin for secondary prevention
Cohort 2	Acetylsalicylic Acid (Aspirin, BAYE4465)	hypothetical UK populations of adults aged 50-59 take low-dose aspirin for secondary prevention
Cohort 1	Acetylsalicylic Acid (Aspirin, BAYE4465)	hypothetical UK populations of adults aged 50-59 take low-dose aspirin for primary prevention

Primary Outcome Measures

Name	Time	Method
Number of myocardial infarction and ischaemic stroke	Up to 20 years	Calculated results using a mimicked population
Number of severe gastrointestinal (GI) bleeding requiring hospitalization	Up to 20 years	Calculated results using a mimicked population
Number of death due to myocardial infarction or due to ischaemic stroke	Up to 20 years	Calculated results using a mimicked population
Number of colorectal cancer (CRC)	Up to 20 years	Calculated results using a mimicked population
Number of symptomatic peptic ulcers requiring hospitalization	Up to 20 years	Calculated results using a mimicked population
Number of deaths due to any other cause	Up to 20 years	Calculated results using a mimicked population
Number of death due to CRC	Up to 20 years	Calculated results using a mimicked population
Number of intracranial hemorrhage (ICH)	Up to 20 years	Calculated results using a mimicked population

Secondary Outcome Measures

Name	Time	Method